← Back

Guilin Sanjin Pharmaceutical Co Ltd

Guilin Sanjin Pharmaceutical Co., Ltd. researches, produces, manufactures, and sells traditional Chinese medicines in China and internationally. Its product portfolio includes Sanjin Tablets, Guilin Watermelon Frost, Vertigo Relief Tablets/Granules, Gecko Asthma Relief Capsules, Lamotrigine Tablets (Anxian), Naomaitai Capsules, and various other remedies. These products target therapeutic areas such as urinary system diseases, oral and pharyngeal medications, cardiovascular and cerebrovascular diseases, nervous system diseases, respiratory diseases, digestive system diseases, musculoskeletal system diseases, and tonifying drugs. Incorporated in 2001 and headquartered in Guilin, China, the company operates as a subsidiary of Guilin SanJin Group Co., Ltd.

Country
Price · split & dividend adjusted
News & notes moving 002275.CS
002275.CS▼

Guilin Sanjin's 2026 interim net profit falls 9.12% to 261 million yuan

Guilin Sanjin released its 2026 interim report, with net profit attributable to the parent company at 261 million yuan, down 9.12% year on year. Total operating revenue was 969 million yuan, down 2.98% year on year. Net cash inflow from operating activities was 160 million yuan, down 49.62% year on year. The latest gross margin was 76.69%, down 5.58 percentage points from the previous quarter. The latest return on equity was 7.99%, down 1.18 percentage points year on year. Diluted earnings per share were 0.44 yuan, down 10.20% year on year.
002275.CS ▼
Jiemian·26dRead more →
002275.CS▲2

Guilin Sanjin's Wholly-Owned Subsidiary Lamotrigine Tablets Expected to Be Selected in the 12th National Drug Procurement

Guilin Sanjin Pharmaceutical announced that its wholly-owned subsidiary, Sanjin Group Hunan Sanjin Pharmaceutical, has had its lamotrigine tablets expected to be selected in the 12th national centralized drug procurement. The product specification is 25 mg, 48 tablets per box, with a procurement cycle from the date the selection results are implemented until December 31, 2029. Lamotrigine tablets are used to treat epilepsy. In 2025, sales revenue was 73.8999 million yuan, accounting for 3.61% of the company's 2025 operating revenue. The company stated that this expected selection will help promote product sales and market expansion, and enhance brand influence, but there is still uncertainty regarding the signing of procurement contracts and subsequent market sales execution.
002275.CS ▲
Jiemian·47dRead more →
© 2026 MarketDXAsset